Victory Capital Management
SRPT icon

Victory Capital Management’s Sarepta Therapeutics SRPT Stock Holding History

Victory Capital Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$298K Buy
16,585
+319
+2% +$6.03K ﹤0.01% 2170
2026
Q1 		$354K Buy
16,266
+1,191
+8% +$23.1K ﹤0.01% 2095
2025
Q4 		$324K Buy
15,075
+1,293
+9% +$27.3K ﹤0.01% 2100
2025
Q3 		$266K Sell
13,782
-3,548
-20% -$63.3K ﹤0.01% 2166
2025
Q2 		$296K Sell
17,330
-50,382
-74% -$2.15M ﹤0.01% 2164
2025
Q1 		$4.32M Sell
67,712
-21,096
-24% -$2.22M ﹤0.01% 1322
2024
Q4 		$10.8M Buy
88,808
+22,529
+34% +$2.76M 0.01% 1066
2024
Q3 		$8.28M Sell
66,279
-16,794
-20% -$2.32M 0.01% 1162
2024
Q2 		$13.1M Buy
83,073
+11,087
+15% +$1.42M 0.01% 978
2024
Q1 		$9.32M Sell
71,986
-3,046
-4% -$373K 0.01% 1082
2023
Q4 		$7.24M Sell
75,032
-12,354
-14% -$1.19M 0.01% 1157
2023
Q3 		$10.6M Buy
87,386
+12,894
+17% +$1.46M 0.01% 992
2023
Q2 		$8.53M Sell
74,492
-3,135
-4% -$404K 0.01% 1093
2023
Q1 		$10.7M Buy
77,627
+20,350
+36% +$2.64M 0.01% 1005
2022
Q4 		$7.42M Sell
57,277
-139,177
-71% -$16.1M 0.01% 1111
2022
Q3 		$21.7M Buy
196,454
+160,708
+450% +$16.2M 0.03% 770
2022
Q2 		$2.68M Sell
35,746
-17,322
-33% -$1.27M ﹤0.01% 1387
2022
Q1 		$4.08M Sell
53,068
-579,212
-92% -$44.4M ﹤0.01% 1326
2021
Q4 		$56.9M Buy
632,280
+621,740
+5,899% +$53.2M 0.05% 514
2021
Q3 		$975K Buy
10,540
+610
+6% +$47K ﹤0.01% 1873
2021
Q2 		$772K Sell
9,930
-134
-1% -$10.2K ﹤0.01% 1987
2021
Q1 		$750K Sell
10,064
-19,342
-66% -$1.78M ﹤0.01% 2034
2020
Q4 		$5.01M Sell
29,406
-3,502
-11% -$519K 0.01% 1240
2020
Q3 		$4.62M Buy
32,908
+21,631
+192% +$3.29M 0.01% 1215
2020
Q2 		$1.81M Sell
11,277
-147
-1% -$20K ﹤0.01% 1472
2020
Q1 		$1.12M Sell
11,424
-40
-0.3% -$4.57K ﹤0.01% 1548
2019
Q4 		$1.48M Sell
11,464
-286
-2% -$28.9K ﹤0.01% 1611
2019
Q3 		$885K Buy
+11,750
New +$1.39M ﹤0.01% 1724

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Victory Capital Management's SRPT Position: Q2 2026 in Review

Victory Capital Management increased its Sarepta Therapeutics (SRPT) stake by 2% in Q2 2026, buying an estimated $6.03K and bringing the position to 16,585 shares worth $298K. The position accounts for ﹤0.01% of the portfolio, ranked #2170.

Victory Capital Management first reported a position in SRPT in Q3 2019 and has held it in 28 quarters since. The position peaked at $56.9M in Q4 2021. 324 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Victory Capital Management held 16,585 shares of Sarepta Therapeutics worth $298K as of Q2 2026.
  • Victory Capital Management bought 319 Sarepta Therapeutics shares in Q2 2026, an estimated $6.03K.
  • Sarepta Therapeutics made up ﹤0.01% of Victory Capital Management's portfolio in Q2 2026, its #2170 holding.
  • Victory Capital Management first reported a position in Sarepta Therapeutics in Q3 2019 and has held it in 28 quarters since.
  • Victory Capital Management's Sarepta Therapeutics position peaked at $56.9M in Q4 2021.
  • 324 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Victory Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.